These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37163814)

  • 1. Design, synthesis, evaluation and optimization of potent IRAK4 inhibitors alleviating production of inflammatory cytokines in LPS-induced SIRS model.
    Hao Y; Wang J; Ma J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Bioorg Chem; 2023 Aug; 137():106584. PubMed ID: 37163814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
    Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
    Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
    Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
    J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo.
    Choudhary SA; Patra D; Sinha A; Mazumder S; Pant R; Chouhan R; Jha AN; Prusty BM; Manna D; Das SK; Tikoo K; Pal D; Dasgupta S
    Eur J Pharmacol; 2023 Apr; 944():175593. PubMed ID: 36804543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
    Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
    J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
    Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
    Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
    Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
    Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
    J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury.
    Zou Y; Wang X; Chen P; Zheng Z; Li X; Chen Z; Guo M; Zhou Y; Sun C; Wang R; Zhu W; Zheng P; Cho WJ; Cho YC; Liang G; Tang Q
    J Med Chem; 2024 Jul; 67(13):10687-10709. PubMed ID: 38913701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.
    Cushing L; Stochaj W; Siegel M; Czerwinski R; Dower K; Wright Q; Hirschfield M; Casanova JL; Picard C; Puel A; Lin LL; Rao VR
    J Biol Chem; 2014 Apr; 289(15):10865-10875. PubMed ID: 24567333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
    Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.